Fred D. Ledley, MD, is the director of the Center for Integration of Science and Industry and a Professor in the Department of Natural and Applied Sciences and Department of
Management and at Bentley University in Waltham, Mass. A recognized opinion leader in the integration of basic biological science with medicine, business, society, and education, he has written more than 170 papers and patent 5 applications in fields ranging from molecular and human genetics and gene therapy to bioethics, biopharmaceutical development, and biotechnology. Ledley has served on the faculties of the Baylor College of Medicine and the Howard Hughes Medical Institute, and was involved in founding several biotechnology companies including GeneMedicine, Inc. and Variagenics Inc. in the area of gene therapy and personalized medicine, serving in roles ranging from VP R&D and CSO, to President & CEO. At Bentley, Ledley spearheaded strategic initiatives to reorganize and reorient the school’s science programs and better prepare business students for leadership roles in technology-driven enterprise. He serves as Chair of the National Biomedical Research Foundation and has served on the Board of Directors of the Massachusetts Biotechnology Council, the Board of Overseers of Boston Children’s Hospital, and as a consultant to industry, academia, and government. His research focuses on strategies for accelerating the translation of scientific discoveries for public benefit. He has a BS from the University of Maryland, an MD from Georgetown University, trained in Pediatrics and Genetics at the Children’s Hospital/Harvard Medical School, and was a post-doctoral fellow with Dr. David Baltimore at the Center for Cancer Research at MIT. (view full bio)
Laura McNamee, PhD, is a Research Associate in the Center for Integration of Science and Industry and Adjunct Assistant Professor of Natural and Applied Science. McNamee has a BS from Merrimack College and a PhD in Biomedical Sciences from the University of Massachusetts Medical School in Worcester where her work focused on experimental models of cancer cell death. As a post-doctoral fellow with Fred Ledley, she led projects looking at patterns of sustaining and disruptive innovation in biotechnology and examined technology metrics that contribute to effective business models within the biotech industry. McNamee is a member of Women Entrepreneurs in Science and Technology (WEST) and is active in the Science Club for Girls, an organization dedicated to promoting STEM education and careers for women. At Bentley, she teaches Human Biology.
Michael Jay Walsh, PhD, is a Post-doctoral Research Fellow at the Center for Integration of Science and Industry. Walsh holds a BA in Chemistry from Colby College where he researched lake water eutrophication and the marine chemistry of iron and superoxide. He obtained a PhD in the field of Environmental Engineering from Cornell University where his work focused on the effect of thiols on the bioavailability of copper to marine algae. While at Cornell, Walsh served as a member of the President’s Climate Commitment Implementation and Sustainable Campus Committees and was elected by the student body to serve on the University’s Board of Trustees. He has received awards from the New York State Water Environment Association and the American Institute of Biological Sciences for his work at the science & policy interface. At the Center, Walsh will research the development of energy and sustainable technologies.
Jennifer Beierlein, PhD, is a Post-doctoral Research Fellow at the Center for Integration of Science and Industry. Beierlein holds a BS in Biochemistry from Russell Sage College. She obtained her PhD in Medicinal Chemistry from the University of Connecticut in 2011, where her research project explored antibiotic drug discovery targeting Anthrax infections. She then joined Brandeis University as a Ruth L. Kirschstein research fellow studying neurodegenerative diseases using yeast as a model organism. During her studies, she has taken an active interest in science policy, including participating in meetings on Capitol Hill and attending AAAS national meetings. At the Center, she will utilize business and technology metrics to research the factors involved in neurodegenerative disease therapeutic development.
Ekaterina (Kat) Galkina Cleary, PhD, is a Post-doctoral Research Fellow at the Center for Integration of Science and Industry at Bentley University. She received her BS in Biology/Bioinformatics from UMass Lowell and MS degree in Bioinformatics from Boston University. She holds a PhD in Biomedical Engineering and Biotechnology from UMass Lowell, where her thesis work focused on statistical modeling of environmental risk factors influencing Alzheimer’s disease progression. Simultaneously, she was project lead on designing an interactive, cartographic visualization of ultrafine particle pollution in the Chinatown region of Boston, MA (an ongoing NIH-funded multi-university project). She is an ambassador for the TZOA wearable air quality tracker and an active member of the Million Women Mentors program. At Bentley she will provide the analytical resources for researching trends in biotech.
Michael Boss, PhD, MBA, is an Executive in Residence at the Center for Integration of Science and Industry at Bentley University. Boss has been a leader in the biotechnology industry for more than 30 years as a scientist and senior executive. As a group leader at Celltech, he was lead inventor of the landmark “Boss patent,” which enabled genetic engineering and manufacture of recombinant, monoclonal antibodies and generated >$1 billion in revenues. Dr. Boss co-founded Oros Instruments, a successful developer of protein purification equipment that was acquired by Biotage. He subsequently joined Genica Pharmaceuticals as Vice President of Research and Development and later Vice President of Operations, where he had a central role in building Genica (renamed Athena Diagnostics) into the leading developer of neurological and genetic tests. Most recently, Boss held the position of Vice President, Corporate Office of Technology, at Elan Corporation and Chief Operating Officer of Xanthus Pharmaceuticals Inc., leading its acquisition by Antisoma, where he continued in senior executive positions. For the past five years, Boss has led the program at Summit Therapeutics, Inc. as Chief Technology Officer to develop a therapy for Duchenne Muscular Dystrophy. Under his leadership the program has progressed from pre-clinical to a proof-of-concept Phase 2 trial that is underway. The program received recent validation in a license deal with Sarepta Therapeutics Inc. for European and Latin American commercial rights that Boss negotiated where Summit received $40 million upfront with a total potential deal value of some $941 million in milestone payments. He has a BSc and PhD from London University and an MBA from London Business School, trained in immunology at ICRF London with Dr. Mel Greaves and Dr. Martin Raff, and was a post-doctoral fellow with Dr. David Baltimore at the Center for Cancer Research at MIT.
Nancy Hsiung, PhD, is an Executive in Residence at the Center for Integration of Science and Industry at Bentley University. She has more than 30 years of experience in the biotechnology industry, in both scientific and managerial positions as well as in the investment community. For the past 11 years, Hsiung worked with GeneChem Management Inc, a venture fund headquartered in Montreal, where her responsibilities included sourcing, assessing and managing investment opportunities. Prior to GeneChem, Nancy was a consultant whose activities range from strategic planning, business development, technology assessment, market research and financing for biotechnology and biopharmaceutical companies. She started her career on the operational side as a scientist with Integrated Genetics (now part of Genzyme, now Sanofi) where she established the company's gene expression and tissue culture capabilities, as a member of the management team at Applied Biotechnology, whose focus was on vaccines and oncology and as the U.S. head of Corporate Development for Toyobo Corporation's (a large Japanese multinational) biopharmaceutical division. Hsiung received a BA degree from the University of Pennsylvania and a PhD degree in chemistry from Columbia University; she completed her post-doctoral studies in molecular biology at Yale University and Princeton University. She holds more than 15 patents and patent applications worldwide and has written 12 publications/abstracts.
Dr. Mark Adams, PhD, has been working in data analytics for almost 20 years, including work in computational biology, biomedicine, intelligence, finance and biotechnology. He has been right in the middle of the remarkable story of Big Data, in some of the most interesting places where data analytics have been developed and used. He is currently the Chief Information Officer for the biotechnology company Celmatix Inc. in New York City, where he works on the genomics of women's health and infertility. Previous positions included Bridgewater Associates, Ltd., where he developed unique data warehousing and machine learning approaches to support the world’s largest hedge fund. Dr. Adams has also worked in other medical and biotechnology settings, including almost ten years at Booz Allen Hamilton, where he developed a leading biomedical informatics consulting practice with a primary focus on informatics strategy for clients in the commercial, government, and non-profit markets. From hacking the human genome to protecting the public from bioterrorism, Dr. Adams has led some of the earliest efforts to make sense of Big Data, and is excited to share his experience with everyone. Dr. Adams holds a B.A. from Oberlin College and a PhD from Baylor College of Medicine.
Stephen Atkinson, is an Executive in Residence at the Center for Integration of Science and Industry at Bentley University. He has 35+ years of experience managing life science technology commercialization in academic and corporate organizations. Since 1997, Mr. Atkinson has been principal of Atkinson & Associates, an international consulting practice specializing in new venture development, technology-based business transactions, project management and intellectual property strategy. He served for nine years as a Senior Consultant for the Copenhagen-based firm, Plougmann Vingtoft. He also served as a consultant to Mount Sinai Innovation Partners at the Icahn School of Medicine at Mount Sinai where he led negotiation of a universal flu vaccine alliance with GlaxoSmithKline. Previously, he was Deputy Director for Business Development at MassBiologics (MBL), where he negotiated an alliance with Merck to commercialize MBL’s C. difficile product. He was Vice President for Commercial Development at Sanofi Pasteur Biologics, where he established and managed government and corporate partnerships. He founded and directed Harvard’s technology development programs, licensing multiple technologies that have been successfully brought to market. He negotiated multiple R&D collaborations with multi-national pharmaceutical firms and was the architect for Medical Science Partners, the Medical School's venture fund. Mr. Atkinson held multiple leadership roles for the Association of University Technology Managers (AUTM), including President, Trustee and Board Member. He has an A.B. from Harvard College and completed intellectual property law, contract and technology commercialization courses at Harvard Law School and Georgetown University.
Current Undergraduate Researchers
Usama Salim '17
Roger Du '18
Adrine Harutyunyan '18
Skyler DeBoer '18
Jonathan Lee '19
Current Graduate Researchers
Christopher Bresten, UMass Dartmouth '17
Nilam Shete '17
Vedat Uzdil '11
Eric Ndung’u '12
Katie DiTomaso '13
Aaron Perlman '13
Ashley Rossi '13
Peter Connolly '14
JR Brennan '15
Cory Kalin '15
Rachel Spero, Northeastern '15
Quinyi "Agnes" Xu, '15
Ryan Belleville, UMass Lowell '16
Akshay Prakash '16
Jake Wegweiser '17
Katherine Adams, MIT '20